Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daraxonrasib + Darlifarnib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daraxonrasib | Rasonque | RMC 6236|RMC6236|RMC-6236 | RAS Inhibitor (Pan) 16 | Rasonque (daraxonrasib) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). Rasonque (daraxonrasib) is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
| Darlifarnib | KO 2806|KO2806|KO-2806 | Farnesyltransferase Inhibitor 4 | Darlifarnib (KO-2806) is a farnesyltransferase inhibitor, which may inhibit the Mtor pathway, leading to cell cycle arrest and inhibition of cell growth (Mol Cancer Ther (2023) 22 (12_Supplement): B024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|